Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study Abstract PS104

Wyles DL, Brau N, Kottilil S, et al. Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study Abstract PS104. In International Liver Congress 2016. April 13-17. Barcelona, Spain; 2016.

Publication Type:

Conference Paper

Authors:

D L Wyles; Brau, N.; Kottilil, S.; et, al

Source:

International Liver Congress 2016. April 13-17., Barcelona, Spain (2016)

Abstract:

PS104

Cited On:

Export Citation:
RIS Format
Top